Clinical observation of ezetimibe co-administration with sulodexide adjusting lipids and anti-inflammation in elderly patients with CHD and DM

Objective To investigate the therapeutic effectiveness and safety of ezetimibe combined with sulodexide on overall lipid-adjusting,lowering TNF-αand CRP in elderly patients with CHD and DM.Methods 180 elderly patients with CHD,DM were divided equally into 3 groups.All the subjects received therapy as follows:①10 mg ezetimibe qd.+250 LSU sulodexide bid(the observed group,n=60);②10 mg ezetimibe qd +20 mg simvastatin qd.(the 1st control group,n=60);③20 mg simvastatin qd.(the 2nd control group,n=60).Serum total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),total triglyeride(TG) were determined before treatment,at 4 weeks and at 12 weeks;serum tumor necrosis factor-α(TNF-α) and C-reactive protein(CRP) were also determined before treatment and at 12 weeks.Results ①TC and LDL-C in the 3 groups were significantly lower(P0.05) after treatment compared with the basic level.TC and LDL-C were significantly lower in the 1st control group than the observed group(P0.05),and lower in the observed group than the 2nd control group(P0.05)at 12 weeks.②HDL-C was significantly higher in the observed group compared with the basic level at 12 weeks.③TG was significantly lower in the observed group and the 1st control group compared with their respective baseline(P0.05),and in the observed group than the 1st control group at 4 weeks and at 12 weeks(P0.05).④At 12 weeks,the compliance rates of TC,LDL-C,HDL-C and TG in the observed group were higher than in the 2nd control group respectively;the compliance rate of TG in the observed group was higher than in the 1st control group;the compliance rates of TC and LDL-C in the 1st control group were the highest(reached at 100%) than the other 2 groups.⑤TNF-α and CRP were significantly lower in the 3 groups compared with their respective baseline(P0.05),and there was no difference on the therapeutic effectiveness between in the 3 groups.Conclusion Ezetimibe co-administration with sulodexide in elderly patients with CHD and DM can not only show pleiotropic effects on overall lipid-adjusting,anti-inflammation,good safeness,but also can educes classical pharmacological actions of sulodexide,so it is a prospective clinical medication combination.